Skip to main content
    I

    Integra LifeSciences Holdings (IART)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $13.98
    -0.42 (-2.92%)

    Market Cap: $1.12B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Integra LifeSciences Holdings (IART) Financials: Revenue, Profit and Cash Flow

    Updated Oct 21, 2026. Financial statements from company filings, amounts in US dollars.

    Integra LifeSciences Holdings reported revenue of $1.64B for the fiscal year ended Dec 31, 2025, up 1.5% from the year before. That year, net income was -$516.47M with a net margin of -31.6%, operating cash flow was $50.38M and free cash flow was -$31.05M. The quarter ended Sep 30, 2026 had revenue of $411.18M and net income of $14.85M.

    Revenue and Margins

    The operating margin was -30.2% in the fiscal year ended Dec 2025, the lowest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $992.08M, a compound annual rate of 5.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$1.64B+1.5%50.9%-30.2%-31.6%
    Dec 2024$1.61B+4.5%54.8%1.8%-0.4%
    Dec 2023$1.54B-1.0%57.4%7.2%4.4%
    Dec 2022$1.56B+1.0%62.3%15.3%11.6%
    Dec 2021$1.54B+12.4%61.2%12.8%11.0%
    Dec 2020$1.37B-9.6%62.0%11.0%9.8%
    Dec 2019$1.52B+3.1%62.8%6.2%3.3%
    Dec 2018$1.47B+23.9%61.2%7.5%4.1%
    Dec 2017$1.19B+19.8%63.3%3.8%5.4%
    Dec 2016$992.08MN/A64.8%11.6%7.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$1.64B$1.61B$1.54B$1.56B$1.54B$1.37B$1.52B$1.47B$1.19B$992.08M
    Cost of revenue$803.63M$728.47M$656.84M$587.36M$597.81M$520.83M$564.68M$571.50M$435.51M$349.09M
    Gross profit$831.62M$882.06M$884.74M$970.31M$944.64M$851.03M$952.88M$900.95M$752.73M$642.99M
    Research and development$98.97M$115.38M$104.19M$101.19M$93.05M$77.38M$144.49M$78.04M$63.45M$58.16M
    Operating income-$493.37M$28.41M$111.53M$238.92M$197.23M$151.37M$93.76M$111.00M$44.80M$115.34M
    Net income-$516.47M-$6.94M$67.74M$180.55M$169.07M$133.89M$50.20M$60.80M$64.74M$74.56M
    EBITDA-$338.28M$178.84M$244.92M$376.71M$378.17M$283.91M$218.13M$236.29M$137.82M$191.38M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$411.18M$418.76M$391.92M$434.93M$402.06M$415.61M$382.65M$442.65M$380.83M$418.18M$368.87M$397.04M
    Gross profit$209.87M$219.74M$216.98M$220.87M$206.99M$209.33M$194.43M$249.07M$200.24M$225.92M$206.83M$226.49M
    Operating income$18.90M$19.29M$11.47M$23.04M$11.76M-$512.67M-$15.50M$35.63M-$8.15M-$3.03M$3.96M$36.05M
    Net income$14.85M$4.48M-$4.62M-$1.70M-$5.40M-$484.07M-$25.29M$19.43M-$10.70M-$12.40M-$3.28M$19.83M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $1.86B exceeded cash and equivalents by $1.62B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$3.60B$4.04B$3.78B$3.89B$3.78B$3.62B$3.30B$3.11B$3.21B$1.81B
    Current assets$1.16B$1.08B$1.06B$1.16B$1.15B$1.24B$858.17M$775.08M$822.15M$495.17M
    Cash and equivalents$235.05M$246.38M$276.40M$456.66M$513.45M$470.17M$198.91M$138.84M$174.94M$102.06M
    Total liabilities$2.56B$2.49B$2.19B$2.09B$2.10B$2.10B$1.89B$1.73B$2.25B$968.29M
    Short-term debt$126.55M$607.08M$14.53M$38.13M$45.00M$146.25M$45.00M$22.50M$82.79M$0
    Long-term debt$1.73B$1.20B$1.49B$1.41B$1.50B$1.41B$1.30B$1.33B$1.78B$665.00M
    Shareholder equity$1.04B$1.55B$1.59B$1.80B$1.68B$1.51B$1.42B$1.38B$962.31M$839.67M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$3.51B$3.56B$3.58B$3.60B$3.65B$3.67B$4.05B$4.04B$4.07B$4.07B$4.08B$3.78B
    Total liabilities$2.44B$2.52B$2.54B$2.56B$2.61B$2.63B$2.53B$2.49B$2.54B$2.54B$2.48B$2.19B
    Cash and equivalents$252.26M$214.41M$236.81M$235.05M$232.19M$217.91M$239.10M$246.38M$215.16M$215.24M$591.91M$276.40M
    Shareholder equity$1.07B$1.04B$1.04B$1.04B$1.04B$1.04B$1.52B$1.55B$1.52B$1.53B$1.60B$1.59B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, capital expenditures exceeded operating cash flow, leaving negative free cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$50.38M$129.38M$139.96M$264.47M$312.43M$203.83M$231.43M$199.68M$114.54M$116.41M
    Capital expenditures$81.44M$104.42M$66.86M$42.34M$48.02M$38.89M$69.54M$77.74M$43.50M$47.33M
    Free cash flow-$31.05M$24.96M$73.09M$222.13M$264.40M$164.94M$161.90M$121.94M$71.04M$69.08M
    Dividends paidN/AN/A$93.24M$5.46M$2.02M$44.56M$434.00KN/A$0$0
    Share repurchases$221.00K$52.47M$275.00M$125.00M$0$100.00M$0$0N/AN/A
    Investing cash flow-$108.06M-$390.81M-$94.18M-$58.58M-$161.44M-$68.07M-$162.67M-$49.70M-$1.22B-$42.62M
    Financing cash flow$28.34M$237.86M-$229.93M-$251.95M-$98.23M$121.63M-$8.77M-$180.87M$1.17B-$15.12M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$95.98M$22.80M$9.80M$11.82M$40.91M$8.92M-$11.26M$50.74M$22.48M$40.40M$15.76M$58.75M
    Capital expenditures$10.25M$12.31M$14.85M$17.21M$15.16M$20.15M$28.92M$29.60M$29.65M$29.71M$15.46M$24.54M
    Free cash flow$85.73M$10.49M-$5.04M-$5.40M$25.75M-$11.23M-$40.18M$21.14M-$7.16M$10.69M$291.00K$34.22M
    Last 12 quarters

    Frequently Asked Questions About IART

    What is Integra LifeSciences Holdings' annual revenue?

    Integra LifeSciences Holdings reported revenue of $1.64B for the fiscal year ended Dec 31, 2025.

    How fast is Integra LifeSciences Holdings' revenue growing?

    Revenue was up 1.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.6%.

    Is Integra LifeSciences Holdings profitable?

    No. Integra LifeSciences Holdings reported net income of -$516.47M for the fiscal year ended Dec 31, 2025, with a net margin of -31.6%.

    How much free cash flow does IART generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $50.38M minus capital expenditures of $81.44M produced free cash flow of -$31.05M.

    How much debt does Integra LifeSciences Holdings have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.73B, short-term debt of $126.55M and cash and equivalents of $235.05M.